News

GE sequences stem cells in China
Enlarge image

ResearchUK

GE sequences stem cells in China

13.06.2012 - A new partnership will bring GE Healthcare information on racial genetic variations in stem cells.

Chalfont St Giles/Bejing  – GE Healthcare has launched a stem cell cooperation in China. Together with the Bejing Genomics Institute (BGI), the UK-based healthcare unit of the US technology major will perform a multi-year research collaboration in stem cell science. The Chinese sequencing specialist will help to explore the underlying genetic variation between ethnically diverse human stem cell lines, which may help to help advance the potential of stem cell-derived assays for use in drug discovery and toxicity testing. 

GE and the BGI made the collaboration public at a special signing ceremony attended by Amr Abid, General Manager Cell Technologies at GE Healthcare Life Sciences and the three leading executives from the BGI. Two projects are planned in the frame of the cooperation. As a first project, BGI is performing genome sequencing and epigenetic analysis on cardiomyocytes and hepatocytes supplied by GE Healthcare Life Sciences. The aim is to map the genetic variation across an ethnically diverse range of stem cell lines and to examine the changes that occur during differentiation into specific cell types. As a basis for the second project, GE Healthcare will provide BGI with a IN Cell Analyzer 2000 system for high content cellular imaging analysis. The analyzer will be used by BGI to investigate gene function for a library of previously sequenced cell types by over-expressing or blocking the activity of single genes and observing the effect in selected populations of cells.

http://www.european-biotechnology-news.com/news/news/2012-02/ge-sequences-stem-cells-in-china.html

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

FinancingGermanyNetherlandsEU

12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.

Event ReviewGermanyEU

08.04.2016 Do you win by being innovative?, was the question asked at this year’s DIA Euromeeting in Hamburg. In a relaxed and cooperative atmosphere, regulators, physicians and patients had ample opportunity to interact with the healthcare industry.

M&AIrelandEU

07.04.2016 Pfizer and Allergan have called off their merger, cancelling plans to relocate the US pharma giant to Ireland to avoid US taxation. The US government has put a spoke in Pfizer’s wheels - an unfair move, Allergan says.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • THERAMETRICS (CH)0.03 CHF50.00%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • OXFORD BIOMEDICA (UK)5.52 GBP-8.76%
  • IXICO (UK)39.00 GBP-4.88%
  • BIONOR PHARMA (N)0.85 NOK-4.49%

TOP

  • AB SCIENCE (F)19.21 EUR71.5%
  • SYNAIRGEN (UK)36.25 GBP48.0%
  • BIOFRONTERA (D)3.14 EUR38.3%

FLOP

  • EVOLVA (CH)0.68 CHF-26.1%
  • SERODUS (N)1.70 NOK-26.1%
  • THERAMETRICS (CH)0.03 CHF-25.0%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.40 SEK2065.5%
  • NICOX (F)8.73 EUR352.3%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.00 SEK-88.2%
  • BB BIOTECH (D)47.86 EUR-81.9%
  • BIOTEST (D)17.00 EUR-77.0%

No liability assumed, Date: 28.04.2016